how the value of cryptocurrency is determined Top Knowledge

Hailide: PPS filament products have not yet been involved in the field of humanoid robots. Hailide said on the interactive platform on December 13th that the company has been deeply involved in the field of materials for many years, and with the continuous investment in research and development, the commercialization of PPS filament has been realized. At present, the product has not yet been involved in the field of humanoid robots. In the future, the company will strive to gradually realize mass production applications in related emerging fields, and is full of confidence in this.Hisense Jia Shaoqian: Brand building is very hard work, which requires long-term persistence and a lot of money. The annual meeting of Caijing 2025: Forecast and Strategy and 2024 Global Wealth Management Forum was held in Beijing from December 13th to December 15th. Jia Shaoqian, Chairman of Hisense Group, delivered a speech. Jia Shaoqian pointed out that whether it is globalization or transformation, the key to the success of strategy lies in persistence and implementation to the end. He bluntly said that branding is a very hard job, which requires long-term persistence and a lot of money. Hisense firmly believes in the power of brands, that brands are the future of enterprises, and that there is no internationalization of Hisense without the internationalization of brands. "Especially when most China enterprises take advantage of the dividends from entering the market and borrow ships to go out to sea through OEM to make quick money, Hisense voluntarily gave up OEM and chose the most difficult shipbuilding to go out to sea, that is, resolutely went to the high end and invested a lot of money, people and resources in brand building, especially in corporate marketing." He said. (Rui Jian)Hengrui Pharma: SHR-2173 injection was approved for clinical trial. Hengrui Pharma announced that its subsidiary, Guangdong Hengrui Pharma Co., Ltd., received the Notice of Approval for Clinical Trial of SHR-2173 injection approved and issued by National Medical Products Administration, and agreed to carry out clinical trial. The indication is lupus nephritis. SHR-2173 injection is a therapeutic biological product independently developed by the company, and the research and development expenses have been invested about 45.03 million yuan. The period from research and development to listing of drugs is long, there are many links, and there are uncertain factors. The company will actively promote research and development projects and fulfill its information disclosure obligations.

AI glasses ushered in the limelight, and Google reached a cooperation with domestic manufacturers. According to the news, on December 13, at the Android XR conference, Google reached a strategic cooperation with domestic consumer-grade AR glasses manufacturer XREAL to jointly build the Android XR ecosystem. According to media reports, OPPO, vivo, Huawei, Tencent and ByteDance are all evaluating the AI glasses project. In addition, a number of listed companies said on the investor question and answer platform that they have corresponding technology or product reserves in AI glasses. Huaxin Securities Research Report pointed out that AI glasses have become a new outlet in the smart wear market, or lead the next generation of terminal revolution. AI glasses not only have the effect of virtual vision enhancement, but also realize real-time analysis of user behavior and environment by integrating artificial intelligence algorithms, providing more accurate and personalized services. AI glasses also improve comfort and prolong wearing time in design and portability. At the same time, it provides a more natural and convenient interactive experience innovation through various sensing technologies. With the gradual reduction of costs, AI glasses are expected to be further widely used. According to the report of Wellsenn XR, it is estimated that after 2030, the AI+AR smart glasses industry will enter a period of rapid development; By 2035, AI+AR smart glasses will eventually replace traditional smart glasses, and the global sales of AI+AR smart glasses will reach 1.4 billion units, which is equivalent to the size of smart phones and will become the next generation general computing platform and terminal. (Securities Times)Wen Ning Ke, former CEO of ASML, will be the chairman of the supervisory board of Heineken in April next year. Heineken Holdings announced on December 13th that Peter Wen Ning Ke, vice chairman of the supervisory board and former CEO of ASML, will be the chairman of the supervisory board in April next year, replacing Jean-Marc Huët. Wen Ning Ke joined the Board of Supervisors of Heineken at this year's annual general meeting of shareholders, and is an important member of the Audit Committee, Remuneration Committee and Selection and Appointment Committee.Changshu Automobile Accessories: It is planned to invest 22.8 million yuan to set up a joint venture with Antonlin Investment Co., Ltd. Changshu Automobile Accessories announced that the company plans to set up a joint venture with Antonlin Investment Co., Ltd. in Wuhu City, Anhui Province, tentatively named Wuhu Antonlin Intelligent Cockpit System Co., Ltd., with an estimated total investment of 140 million yuan, including a registered capital of 57 million yuan. The company invested 22.8 million yuan, accounting for 40% of the total share capital of Antonglin in Wuhu; Antonglin Investment Co., Ltd. contributed 34.2 million yuan, accounting for 60% of the total share capital of Antonglin in Wuhu. The establishment of the new company will expand the company's industrial layout, improve the company's comprehensive competitive strength and realize the company's strategic plan for sustainable development.

Hengrui Pharma: SHR-2173 injection was approved for clinical trial. Hengrui Pharma announced that its subsidiary, Guangdong Hengrui Pharma Co., Ltd., received the Notice of Approval for Clinical Trial of SHR-2173 injection approved and issued by National Medical Products Administration, and agreed to carry out clinical trial. The indication is lupus nephritis. SHR-2173 injection is a therapeutic biological product independently developed by the company, and the research and development expenses have been invested about 45.03 million yuan. The period from research and development to listing of drugs is long, there are many links, and there are uncertain factors. The company will actively promote research and development projects and fulfill its information disclosure obligations.Wang Honghai, former chairman of the Financial and Economic Committee of Tianjin Municipal People's Congress, was "double-opened" for illegal intervention and intervention in judicial activities. Recently, with the approval of the Tianjin Municipal Committee of the Communist Party of China, the Supervision Committee of Tianjin Municipal Commission for Discipline Inspection filed a case review and investigation on Wang Honghai, former member of the Standing Committee of the Municipal People's Congress, former chairman of the Financial and Economic Committee of the Municipal People's Congress and former director of the Budget Working Committee of the Standing Committee of the Municipal People's Congress. After investigation, Wang Honghai lost his ideals and beliefs, abandoned his initial mission, resisted organizational censorship, and personally engaged in superstitious activities; Ignoring the spirit of the eight central regulations, repeatedly accepting gifts and gifts in violation of regulations, arranging family members to accept tourism activities that may affect the fair execution of official duties, and borrowing vehicles for management services for a long time without compensation; Violation of organizational principles, using authority to seek benefits for others in the promotion and adjustment of cadres' positions; Violation of regulations and intervention in judicial activities, improper performance of duties in the work, resulting in adverse effects; Taking public power as a tool for personal gain, taking advantage of his position to make profits for others in project contracting and job transfer, and illegally accepting huge amounts of property.Comments on Hong Kong stocks: Hang Seng Index fell by 2.09%, Hang Seng Technology Index fell by 2.63%, Hong Kong stocks closed, Hang Seng Index fell by 2.09% and Hang Seng Technology Index fell by 2.63%. Domestic insurance stocks and domestic housing stocks were among the top losers, with Sunac China falling more than 8%, and Xpeng Motors, China Pacific Insurance and Zijin Mining falling more than 5%.